Alzheimer's and ABC transporters - new opportunities for diagnostics and treatment

NEUROBIOLOGY OF DISEASE

卷:72

Review

Pahnke, Jens^1,2  Langer, Oliver^3,4  Krohn, Markus¹ 

[1] Univ Magdeburg, Dept Neurol, Neurodegenerat Res Lab, D-39120 Magdeburg, Germany

[2] German Ctr Neurodegenerat Dis DZNE, D-39120 Magdeburg, Germany

[3] AIT Austrian Inst Technol, Hlth & Environm Dept, A-2444 Seibersdorf, Austria

[4] Med Univ Vienna, Dept Clin Pharmacol, A-1090 Vienna, Austria

关键词: ABC transporter;    Alzheimer's disease;    Neurodegeneration;    Blood-brain barrier;    BBB;    Choroid plexus;    ABCB1;    ABCC1;    ABCA7;    Glymphatic system;    Amyloid-beta;    PET;   

DOI  :  10.1016/j.nbd.2014.04.001

来源: Elsevier

【 摘 要 】

Much has been said about the increasing number of demented patients and the main risk factor 'age'. Frustratingly, we do not know the precise pattern and all modulating factors that provoke the pathologic changes in the brains of affected elderly. We have to diagnose early to be able to stop the progression of diseases that irreversibly destroy brain substance. Familiar AD cases have mislead some researchers for almost 20 years, which has unfortunately narrowed the scientific understanding and has, thus, lead to insufficient funding of independent approaches. Therefore, basic researchers hardly have been able to develop causative treatments and clinicians still do not have access to prognostic and early diagnostic tools. During the recent years it became clear that insufficient A beta export, physiologically facilitated by the ABC transporter superfamily at the brain's barriers, plays a fundamental role in disease initiation and progression. Furthermore, export mechanisms that are deficient in affected elderly are new targets for activation and, thus, treatment, but ideally also for prevention. In sporadic AD disturbed clearance of beta-amyloid from the brain is so far the most important factor for its accumulation in the parenchyma and vessel walls. Here, we review findings about the contribution of ABC transporters and of the perivascular drainage/glymphatic system on beta-amyloid clearance. We highlight their potential value for innovative early diagnostics using PET and describe recently described, effective ABC transporter-targeting agents as potential causative treatment for neurodegenerative proteopathies/dementias. (C) 2014 Elsevier Inc. All rights reserved.

【 授权许可】

Free